# åˆ¶è¯æ—¥æŠ¥ Pharma Daily

**æ—¥æœŸ**: 2026-02-01
**æ›´æ–°æ—¶é—´**: 2026-02-02 04:23
**æ–°é—»æ•°é‡**: 105

---

## ä»Šæ—¥æ¦‚è§ˆ

## ğŸ“Š AI æ™ºèƒ½åˆ†æ

### ä»Šæ—¥æ¦‚è§ˆ

ä»Šæ—¥åˆ¶è¯è¡Œä¸šåŠ¨æ€èšç„¦äºè‚¥èƒ–ç—‡è¯ç‰©é¢†åŸŸçš„æ¿€çƒˆç«äº‰ä¸é‡ç£…åˆä½œï¼Œä»¥åŠç›‘ç®¡å®¡æ‰¹ä¸ç”Ÿäº§æ‰©å¼ ã€‚é˜¿æ–¯åˆ©åº·å®£å¸ƒä¸ä¸­å›½CSPCè¾¾æˆä»·å€¼è¶…180äº¿ç¾å…ƒçš„è‚¥èƒ–ç—‡è¯ç‰©åˆä½œï¼Œç¤¼æ¥åˆ™å…¬å¸ƒ35äº¿ç¾å…ƒæ–°å·¥å‚ä»¥æ‰©å¤§äº§èƒ½ï¼›åŒæ—¶ï¼Œè¯ºå’Œè¯ºå¾·ä¸ç¤¼æ¥çš„GLP-1ç±»è¯ç‰©åœ¨æ¬§æ´²ç›‘ç®¡æ–¹é¢å–å¾—è¿›å±•ä¸æŒ«æŠ˜å¹¶å­˜ã€‚

### ğŸ”¥ é‡ç‚¹æ–°é—»

**18. AstraZeneca leans into obesity, striking wide-ranging alliance with Chinaâ€™s CSPC** â­â­â­â­â­
   - ç±»åˆ«: å•†ä¸šåŠ¨æ€
   - é˜¿æ–¯åˆ©åº·ä¸ä¸­å›½CSPCè¾¾æˆä»·å€¼å¯èƒ½è¶…è¿‡180äº¿ç¾å…ƒçš„è‚¥èƒ–ç—‡è¯ç‰©åˆä½œï¼Œæ˜¯åŒç±»æˆæƒåè®®ä¸­è§„æ¨¡æœ€å¤§çš„ï¼Œæ ‡å¿—ç€å…¨çƒè¯ä¼åœ¨è‚¥èƒ–ç—‡é¢†åŸŸç«äº‰ç™½çƒ­åŒ–ã€‚

**11. Lilly rounds out quartet of new US plants with $3.5B injectable and device facility in PA** â­â­â­â­â­
   - ç±»åˆ«: å•†ä¸šåŠ¨æ€
   - ç¤¼æ¥å®£å¸ƒæŠ•èµ„35äº¿ç¾å…ƒåœ¨ç¾å›½å»ºè®¾æ–°çš„æ³¨å°„å‰‚å’Œè£…ç½®å·¥å‚ï¼Œä»¥æ”¯æŒå…¶ä¸‹ä¸€ä»£è‚¥èƒ–ç—‡è¯ç‰©retatrutideç­‰äº§å“çš„ç”Ÿäº§ï¼Œå‡¸æ˜¾å…¶å¯¹è‚¥èƒ–ç—‡å¸‚åœºçš„å·¨å¤§äº§èƒ½æŠ•å…¥ã€‚

**2. CHMP thumbs-up Novo's semaglutide for MASH, as Amgen gets Tavneos re-review on data integrity concerns** â­â­â­â­
   - ç±»åˆ«: ç›‘ç®¡å®¡æ‰¹
   - è¯ºå’Œè¯ºå¾·çš„å¸ç¾æ ¼é²è‚½è·æ¬§æ´²CHMPæ”¯æŒç”¨äºMASHï¼ˆä»£è°¢åŠŸèƒ½éšœç¢ç›¸å…³è„‚è‚ªæ€§è‚ç‚ï¼‰ï¼Œè¿™æ˜¯å…¶GLP-1è¯ç‰©åœ¨é‡è¦é€‚åº”ç—‡ä¸Šçš„å…³é”®ç›‘ç®¡è¿›å±•ã€‚

**23. CHMP opposes Lillyâ€™s Mounjaro in heart failure, backs Novoâ€™s Kayshild** â­â­â­â­
   - ç±»åˆ«: ç›‘ç®¡å®¡æ‰¹
   - æ¬§æ´²CHMPæ‹’ç»æ‰¹å‡†ç¤¼æ¥çš„Mounjaroç”¨äºå¿ƒè¡°æ²»ç–—ï¼Œè€Œæ”¯æŒè¯ºå’Œè¯ºå¾·çš„å¸ç¾æ ¼é²è‚½ç”¨äºè‚ç—…ï¼Œåæ˜ äº†GLP-1ç±»è¯ç‰©åœ¨ä¸åŒé€‚åº”ç—‡ä¸Šçš„ç›‘ç®¡å·®å¼‚ä¸ç«äº‰æ€åŠ¿ã€‚

**1. Amgen ends partnership with Kyowa Kirin on immunology drug, despite Phase 3 wins** â­â­â­â­
   - ç±»åˆ«: å•†ä¸šåŠ¨æ€
   - å®‰è¿›åœ¨IIIæœŸæˆåŠŸçš„æƒ…å†µä¸‹çªç„¶ç»ˆæ­¢ä¸åå’Œéº’éºŸåœ¨å…ç–«å­¦è¯ç‰©ä¸Šçš„åˆä½œï¼Œæ¶‰åŠå…³é”®ç®¡çº¿èµ„äº§ï¼Œå¼•å‘å¯¹åˆä½œç¨³å®šæ€§å’Œèµ„äº§ä»·å€¼çš„å…³æ³¨ã€‚

### ğŸ“ åˆ†ç±»æ‘˜è¦

**æ–°è¯ç ”å‘** (Drug R&D): ä»Šæ—¥æ–°è¯ç ”å‘åŠ¨æ€æ´»è·ƒï¼Œæ¶‰åŠå¤šä¸ªé¢†åŸŸã€‚è‚¥èƒ–ç—‡æˆä¸ºç„¦ç‚¹ï¼Œé˜¿æ–¯åˆ©åº·ä¸CSPCåˆä½œå¼€å‘ä¸‹ä¸€ä»£å‡è‚¥è¯ï¼Œç¤¼æ¥ä¹Ÿé€šè¿‡åˆä½œå¸ƒå±€åŸºå› ç¼–è¾‘æ²»ç–—å¬åŠ›æŸå¤±ã€‚æ­¤å¤–ï¼ŒTenpointçš„è€èŠ±çœ¼æ»´çœ¼æ¶²è·æ‰¹ã€Argo Biopharmaçš„siRNAç–—æ³•è¿›å…¥IIbæœŸã€UltragenyxåŸºå› ç–—æ³•é‡æ–°æäº¤ç”³è¯·ï¼Œä»¥åŠå¤šå®¶å…¬å¸ï¼ˆå¦‚Sanofiï¼‰è¿›è¡Œç®¡çº¿è°ƒæ•´ï¼Œå‡æ˜¾ç¤ºäº†è¡Œä¸šåœ¨åˆ›æ–°ç–—æ³•ä¸Šçš„æŒç»­æŠ•å…¥ä¸ç­–ç•¥ä¼˜åŒ–ã€‚
**ä¸´åºŠè¯•éªŒ** (Clinical Trials): ä¸´åºŠè¯•éªŒç›¸å…³æ–°é—»ä¸»è¦å›´ç»•åæœŸé˜¶æ®µç»“æœä¸ç›‘ç®¡äº’åŠ¨ã€‚å®‰è¿›ç»ˆæ­¢åˆä½œçš„å…ç–«å­¦è¯ç‰©å·²å–å¾—IIIæœŸèƒœåˆ©ï¼Œä½†å…¶æ¹¿ç–¹è¯ç‰©å› IIIæœŸç»“æœä»¤äººå¤±æœ›è€Œè¢«æ”¾å¼ƒã€‚Summit Therapeuticsçš„PD-1/VEGFåŒç‰¹å¼‚æ€§æŠ—ä½“è·å¾—FDAçš„PDUFAæ—¥æœŸï¼ŒRocheä¸ºå…¶è‚¥èƒ–ç—‡è¯ç‰©æ•°æ®è¾©æŠ¤ï¼Œè¿™äº›åŠ¨æ€å‡¸æ˜¾äº†ä¸´åºŠè¯•éªŒæ•°æ®å¯¹è¯ç‰©å‘½è¿å’Œå…¬å¸å†³ç­–çš„å…³é”®å½±å“ã€‚

### ğŸ”® æ˜æ—¥å…³æ³¨

éœ€æŒç»­å…³æ³¨é˜¿æ–¯åˆ©åº·ä¸CSPCè‚¥èƒ–ç—‡åˆä½œçš„å…·ä½“è¯ç‰©é¶ç‚¹ä¸æŠ€æœ¯å¹³å°ç»†èŠ‚ï¼›ç•™æ„FDAå¯¹Summit Therapeuticsçš„PD-1/VEGFåŒç‰¹å¼‚æ€§æŠ—ä½“çš„å®¡è¯„è¿›å±•ï¼›è§‚å¯Ÿå®‰è¿›ç»ˆæ­¢åˆä½œåï¼Œè¯¥å…ç–«å­¦èµ„äº§çš„åç»­å¼€å‘è®¡åˆ’åŠå¯¹Kyowa Kirinçš„å½±å“ï¼›ä»¥åŠæ¬§æ´²CHMPå¯¹è¯ºå’Œè¯ºå¾·å¸ç¾æ ¼é²è‚½MASHé€‚åº”ç—‡çš„æœ€ç»ˆå†³å®šã€‚


---

## æ•°æ®ç»Ÿè®¡

| ç±»åˆ« | æ•°é‡ |
|------|------|
| æ–°è¯ç ”å‘ (Drug R&D) | 34 |
| ç»¼åˆ (ç»¼åˆ) | 43 |
| ç›‘ç®¡å®¡æ‰¹ (Regulatory) | 20 |
| å•†ä¸šåŠ¨æ€ (Business/M&A) | 8 |

---

## æ–°è¯ç ”å‘ | Drug R&D

### ğŸ‡ºğŸ‡¸ Amgen ends partnership with Kyowa Kirin on immunology drug, despite Phase 3 wins

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-30 16:04
- **é‡è¦æ€§**: â­â­â­â­â­

> Amgen abruptly pulled out of a collaboration for a leading drug in its immunology pipeline on Friday, sending the asset back to its partner ahead of an FDA submission later this year. Amgen terminated its ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/amgen-ends-partnership-with-kyowa-kirin-on-immunology-drug-despite-phase-3-wins/)

---

### ğŸ‡ºğŸ‡¸ Tenpoint wins FDA nod for combination presbyopia eye drop

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-01-29 12:26
- **é‡è¦æ€§**: â­â­â­â­

> The biotech also raised $235 million in debt and equity funding to support marketing of the drop, which it claims to be an advance over existing treatments from AbbVie and others.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.biopharmadive.com/news/tenpoint-yuvezzi-fda-approve-presbyopia-eye-drop/810743/)

---

### ğŸ‡ºğŸ‡¸ Amgen gives up on its once-prized eczema drug

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-01-30 16:57
- **é‡è¦æ€§**: â­â­â­

> The decision comes more than a year after disappointing initial Phase 3 results and casts further doubt on a class of autoimmune drugs thought to be challengers to treatments like Dupixent.&nbsp;

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.biopharmadive.com/news/amgen-return-rocatinlimab-kyowa-kirin-atopic-dermatitis-eczma-ox40/810964/)

---

### ğŸ‡ºğŸ‡¸ AstraZeneca leans into obesity, striking wide-ranging alliance with Chinaâ€™s CSPC

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-01-30 12:36
- **é‡è¦æ€§**: â­â­

> The deal, which involves up to eight &ldquo;next-generation&rdquo; weight loss medications and could be worth more than $18 billion, ranks as the largest licensing pact of its kind since the start of 2025, according to BioPharma Dive data.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.biopharmadive.com/news/astrazeneca-obesity-deal-china-cspc-ai/810942/)

---

### ğŸ‡ºğŸ‡¸ Politicization runs deeper than ever at FDA, risking long-term impacts

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-01-30 12:00
- **é‡è¦æ€§**: â­â­

> A massive overhaul of staffing and review processes have left the agency appearing heavily driven by the Trump administration&rsquo;s political agenda, according to an economist and public policy expert.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.biopharmadive.com/news/fda-politicization-deeper-than-ever-risking-long-term-impacts/810909/)

---

### ğŸ‡ºğŸ‡¸ Moderna holds a â€˜garage saleâ€™; Roche defends obesity drug data

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-01-29 15:20
- **é‡è¦æ€§**: â­â­

> Moderna licensed out a rare disease drug for what an analyst called a &ldquo;modest&rdquo; sum. Elsewhere, Roche executives suggested better forthcoming obesity results and Summit&rsquo;s PD-1/VEGF blocker got an FDA decision date.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.biopharmadive.com/news/moderna-recordati-roche-obesity-summit-lilly-repertoire/810853/)

---

### ğŸ‡ºğŸ‡¸ Lilly bets on Seamless, delving further into genetic medicine for hearing loss

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-01-28 19:09
- **é‡è¦æ€§**: â­â­

> The potentially $1 billion alliance centered around a flexible gene editing technology adds to a portfolio of cutting-edge treatments the company is developing for hearing disorders.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.biopharmadive.com/news/eli-lilly-seamless-deal-gene-editing-hearing-loss/810694/)

---

### ğŸ‡ºğŸ‡¸ FDA says it explained issues early on for Corcept's rejected Cushing's syndrome drug

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-30 19:14
- **é‡è¦æ€§**: â­â­

> An FDA rejection letter for Corcept Therapeuticsâ€™ potential hormonal disorder drug says the agency told the company it had serious concerns before the application was submitted. The complete response letter, released ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/fda-says-it-explained-issues-early-on-for-corcepts-rejected-cushings-syndrome-drug/)

---

### ğŸ‡ºğŸ‡¸ CHMP opposes Lillyâ€™s Mounjaro in heart failure, backs Novoâ€™s Kayshild

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-30 17:18
- **é‡è¦æ€§**: â­â­

> EU regulators have refused to greenlight Eli Lillyâ€™s weight loss drug Mounjaro as a treatment for a type of heart failure, while giving the go-ahead for Novo Nordiskâ€™s semaglutide in liver disease. Lilly failed to ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/chmp-opposes-lillys-mounjaro-in-heart-failure-backs-novos-kayshild/)

---

### ğŸ‡ºğŸ‡¸ Ultragenyx resubmits gene therapy for rare neuro disease to FDA

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-30 16:50
- **é‡è¦æ€§**: â­â­

> Ultragenyx has resubmitted its approval request for a rare disease gene therapy after the FDA rejected it last summer. UX111 is an AAV gene therapy designed to treat Sanfilippo syndrome type A. The company is ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/ultragenyx-resubmits-gene-therapy-for-rare-neuro-disease-to-fda/)

---

### ğŸ‡ºğŸ‡¸ Lilly unveils $3.5B factory that will make retatrutide and other obesity drugs

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-30 16:00
- **é‡è¦æ€§**: â­â­

> Eli Lilly has budgeted $3.5 billion for a new weight loss injectable and device factory in Lehigh Valley, PA, which will manufacture its next-gen obesity drug retatrutide. The factory will also produce other weight loss ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/lilly-unveils-3-5b-factory-that-will-make-retatrutide-and-other-obesity-drugs/)

---

### ğŸ‡ºğŸ‡¸ AstraZeneca pays $1.2B for CSPC's long-acting obesity drugs

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-30 10:36
- **é‡è¦æ€§**: â­â­

> AstraZeneca is already delivering on its $15 billion commitment to China with a $1.2 billion upfront pact with CSPC Pharmaceutical, spanning eight drug programs and multiple platform technologies. On Thursday, the UK ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/astrazeneca-pays-1-2b-for-cspcs-long-acting-obesity-drugs/)

---

### ğŸ‡ºğŸ‡¸ Pipeline cuts for Sanofi; Breakthru Medicine raises $60M

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-29 15:42
- **é‡è¦æ€§**: â­â­

> âœ‚ï¸ Sanofi culls several programs: The move comes as part of its â€œregular portfolio reviews,â€ a spokesperson said in an email. One candidate affected was amlitelimab, which is no longer in mid-stage trials for alopecia ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/sanofis-pipeline-cuts-breakthru-medicine-raises-60m/)

---

### ğŸ‡ºğŸ‡¸ Summit gets November PDUFA date for its PD-1xVEGF bispecific

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-29 15:07
- **é‡è¦æ€§**: â­â­

> The leader in the next frontier of immuno-oncology officially has a date with the FDA. Summit Therapeutics announced Thursday morning that US regulators have accepted its submission package for the experimental drug ivonescimab, a bispecific ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/summit-gets-november-pdufa-date-for-its-pd-1xvegf-bispecific/)

---

### ğŸ‡ºğŸ‡¸ Agomab anticipates $182M IPO as it builds fibrosis pipeline

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-29 14:13
- **é‡è¦æ€§**: â­â­

> Belgian fibrosis biotech Agomab Therapeutics plans to collect about $182 million in net proceeds from its proposed Nasdaq IPO. The company anticipates selling 12.5 million shares at $15 to $17 each under the ticker symbol ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/agomab-anticipates-182m-ipo-as-it-builds-fibrosis-pipeline/)

---

### ğŸ‡ºğŸ‡¸ Bitterroot reverts to preclinical biotech in CD47 as CEO leaves

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-30 17:30
- **é‡è¦æ€§**: â­

> Bitterroot Bio, a biotech from leading minds in the CD47 field, appears to have returned to the discovery stage after attempting to expand the potential of the "don't eat me" signal from the cancer field ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/bitterroot-reverts-to-preclinical-biotech-in-cd47-as-ceo-leaves/)

---

### ğŸ‡ºğŸ‡¸ Quince's steroid therapy for rare disease fails, shares tank

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-30 16:17
- **é‡è¦æ€§**: â­

> Quince Therapeutics' once-monthly steroid-based treatment failed a Phase 3 trial for a rare genetic condition called ataxia-telangiectasia, prompting the Bay Area company to say it would stop development of the experimental ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/quinces-steroid-therapy-for-rare-disease-fails-shares-tank/)

---

### ğŸ‡ºğŸ‡¸ Moderna licenses Phase 3 asset to Recordati; ProMIS' private placement

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-30 16:05
- **é‡è¦æ€§**: â­

> Plus, news about Lexicon Pharmaceuticals, Vaxcyte, ALX Oncology, BioMarin and 2048 Ventures: ğŸ¤ Moderna signs rare disease drug deal with Recordati: The Italian drugmaker will pay Moderna $50 million upfront and ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/moderna-licenses-phase-3-asset-to-recordati-promis-private-placement/)

---

### ğŸ‡ºğŸ‡¸ Updated: Roche predicts its breast cancer pill could become its biggest-selling drug

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-29 12:11
- **é‡è¦æ€§**: â­

> With two positive clinical readouts in the bag, a US approval filing, and another important trial due to report in a couple months, Rocheâ€™s breast cancer drug giredestrant is sitting pretty. Management is hugely confident ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/roche-predicts-its-breast-cancer-pill-could-become-its-biggest-selling-drug/)

---

### ğŸ‡ºğŸ‡¸ The biopharma industry outlook on 2026: Optimism and tension

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-01-29 19:31

> A spike in M&amp;A activity and stock prices have pulled biotech out of a yearslong downturn. But regulatory tumult and fierce competition from China could short-circuit the sector's resurgence.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.biopharmadive.com/news/biotech-pharma-trends-outlook-2026/810833/)

---

### ğŸ‡ºğŸ‡¸ Sanofi expects vaccine sales growth to dip amid â€˜challenging environmentâ€™

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-01-29 16:56

> On a conference call, executives cited &ldquo;confusion&rdquo; and declining vaccination rates in the U.S. while discussing a quarterly sales decline and anticipated slower growth in 2026. &nbsp;

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.biopharmadive.com/news/sanofi-vaccine-sales-fourth-quarter-2025-earnings/810829/)

---

### ğŸ‡ºğŸ‡¸ AstraZeneca strengthens China ties with planned $15B investment

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-01-29 15:46

> AstraZeneca&rsquo;s&nbsp;investment will &ldquo;span the value chain&rdquo; of drug research and development and comes amid a prolonged surge in dealmaking activity involving large pharmaceutical companies and their counterparts in China.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.biopharmadive.com/news/astrazeneca-china-biotech-invest-drug-manufacturing/810847/)

---

### ğŸ‡ºğŸ‡¸ Drugs for cancer, arthritis and HIV on Medicareâ€™s list for 2028 price cuts

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-01-28 16:51

> Still, the medications in the latest round of negotiations &mdash; which now includes &ldquo;Part B&rdquo; drugs given in doctors offices &mdash; draw very limited revenue from Medicare, an analyst pointed out.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.biopharmadive.com/news/medicare-drug-price-2028-trulicity-biktarvy-verzenio-kisqali/810688/)

---

### ğŸ‡ºğŸ‡¸ Big Pharma earnings kick off; Third-round IRA drugs selected; Hengruiâ€™s trailblazing moment; and more

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-31 11:00

> Welcome back to Endpoints Weekly! Fourth-quarter earnings season is in full swing, and our team covered reports this week from Teva, Roche, Sanofi, Takeda and Regeneron. CMS also unveiled the next 15 drugs subject to ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/big-pharma-earnings-kick-off-third-round-ira-drugs-selected-hengruis-trailblazing-moment-and-more/)

---

### ğŸ‡ºğŸ‡¸ Janux hires CMO after T cell engager deal with Bristol Myers; A batch of appointments at Lexeo

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-30 12:00

> â†’ William Go has replaced Zachariah McIver as CMO of Janux Therapeutics, a San Diego-based biotech that is partnering with Bristol Myers Squibb on a T cell engager ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/janux-hires-cmo-after-t-cell-engager-deal-with-bristol-myers-a-batch-of-appointments-at-lexeo/)

---

### ğŸ‡ºğŸ‡¸ Reed Jobs' cancer biotech investment firm Yosemite eyes $350M fund

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-30 10:45

> Yosemite, the cancer research investment firm led by Reed Jobs, is looking to raise a fund worth up to $350 million, according to a Thursday SEC filing. The California-based investment firm ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/reed-jobs-cancer-biotech-investment-firm-yosemite-eyes-350m-fund/)

---

### ğŸ‡ºğŸ‡¸ Takeda 'anticipated' Medicare negotiations for top seller Entyvio

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-29 19:06

> Incoming Takeda CEO Julie Kim says the drugmaker "anticipated" this week's selection of Entyvio for Medicare negotiations. But for now, the company isn't ready to comment on how the process could affect peak revenue forecasts ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/takeda-anticipated-medicare-negotiations-for-top-seller-entyvio/)

---

### ğŸ‡ºğŸ‡¸ Takeda is â€˜not in favorâ€™ of MFN, CEO-designate says

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-29 18:01

> Takedaâ€™s incoming CEO took a firm stance against President Donald Trumpâ€™s â€œmost favored nationâ€ deals with drugmakers on Thursday, while Sanofi and Roche shared new details about their negotiations with the White House. â€œIn general ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/takeda-is-not-in-favor-of-mfn-ceo-designate-says/)

---

### ğŸ‡ºğŸ‡¸ White House postpones planned TrumpRx launch event

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-29 17:57

> The White House is punting the launch of TrumpRx, the administrationâ€™s hub for direct-to-consumer websites run by large drugmakers. The event was expected to take place Friday, but itâ€™s been postponed, two sources familiar with ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/white-house-postpones-planned-trumprx-launch-event/)

---

### ğŸ‡ºğŸ‡¸ Sanofi vows to stay committed to vaccines as portfolio takes a hit

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-29 16:18

> Sanofi CEO Paul Hudson emphasized the companyâ€™s commitment to vaccine development in the face of an increasingly challenging sales environment and its decision to abandon an mRNA-based flu vaccine program. â€œWe have to continue to ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/sanofi-vows-to-stay-committed-to-vaccines-as-portfolio-takes-a-hit/)

---

### ğŸ‡ºğŸ‡¸ The disrupted fate of pharmacy startups

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-29 16:14

> Last week, the House Judiciary Committee came out with a report about CVS Healthâ€™s alleged antitrust behavior toward disruptive pharmacy models that provide digital services to other pharmacies. It details ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/the-disrupted-fate-of-pharmacy-startups/)

---

### ğŸ‡ºğŸ‡¸ Trump looks to raise South Korea levies; Siegfried expands

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-29 14:42

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/trump-looks-to-raise-south-korea-levies-siegfried-expands/)

---

### ğŸ‡ºğŸ‡¸ AstraZeneca makes $15B bet on China to expand manufacturing and R&D

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-29 13:39

> AstraZeneca, already one of the leading pharmaceutical companies in China, is extending its reach in the country that's become a go-to place for drug R&amp;D and industry dealmaking in the past year. The UK pharma ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/astrazeneca-makes-15b-bet-on-china-to-expand-manufacturing-and-rd/)

---

### ğŸ‡ºğŸ‡¸ Premise Health to merge with Crossover Health to expand employer clinics

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-29 13:00

> Two companies that run on-site health clinics for employers like Google and Amazon are merging as healthcare costs continue to climb. Advanced primary care company Premise Health is acquiring competitor Crossover Health. Both run clinics ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/premise-health-to-merge-with-crossover-health-to-expand-employer-clinics/)

---

## ç»¼åˆ | ç»¼åˆ

### ğŸ‡ºğŸ‡¸ CHMP thumbs-up Novo's semaglutide for MASH, as Amgen gets Tavneos re-review on data integrity concerns

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-30 11:35
- **é‡è¦æ€§**: â­â­â­â­

> Sanofi, Novo Nordisk, UCB and others received positive opinions from Europe's Committee for Medicinal Products for Human Use, while Amgen's approved Tavneos is up for a re-review due to data integrity concerns.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/europes-chmp-thumbs-novos-semaglutide-mash-sanofis-rezurock-and-more-while-amgens-tavneos)

---

### ğŸ‡ºğŸ‡¸ CDMO Vetter maps out expansion in Germany with â‚¬480M for new plant

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-29 17:26
- **é‡è¦æ€§**: â­â­â­

> The German CDMO devoted 480 million euros ($574.3 million) to the first construction phase for a new plant in Saarlouis, Germany, which is expected to be operational by 2031.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/manufacturing/german-cdmo-vetter-takes-global-expansion-spree-its-home-country-eu480m-investment)

---

### ğŸ‡ºğŸ‡¸ A sales turnaround for Regeneron's Eylea franchise will have to wait at least another quarter

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-30 11:15
- **é‡è¦æ€§**: â­â­

> For the last several quarters, declining sales of Regeneron's eye disease treatment Eylea have exceeded increasing sales of the drug's new version, Eylea HD, leading to a steady decline in overall U.S. sales for the Eylea franchise. The company said Friday the trend will continue in the first quarter of this year.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/turnaround-regenerons-eylea-will-have-wait-least-another-quarter)

---

### ğŸ‡ºğŸ‡¸ Lilly rounds out quartet of new US plants with $3.5B injectable and device facility in PA

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-30 09:19
- **é‡è¦æ€§**: â­â­

> On Friday, Eli Lilly unveiled designs on a new, $3.5 billion manufacturing facility in Pennsylvaniaâ€™s Lehigh Valley, rounding out the quartet of plants it promised during its â€œLilly in Americaâ€ investment announcement last year.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/lilly-rounds-out-quartet-new-us-plants-35b-injectables-and-device-facility-pa)

---

### ğŸ‡ºğŸ‡¸ ARS Pharma TV ad for epinephrine nasal spray Neffy needled by FDA in untitled letter

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-29 11:46
- **é‡è¦æ€§**: â­â­

> A few months after sending an untitled letter to ARS Pharmaceuticals, taking issue with certain aspects of a TV commercial about its epinephrine nasal spray, the FDA is reiterating its concerns about Neffyâ€™s advertising language.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/marketing/ars-pharma-tv-ad-epinephrine-nasal-spray-neffy-needled-fda-untitled-letter)

---

### ğŸ‡ºğŸ‡¸ Sanofiâ€™s vaccine ambitions unfazed by â€˜politics or sentiment in the now,â€™ CEO Hudson says

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-29 11:22
- **é‡è¦æ€§**: â­â­

> Amid mounting concerns about the state of vaccine policy in the United States, Sanofi is keeping a cool head while acknowledging that sales of its immunizations are slated to dip slightly this year. The comments come as Sanofi reported Thursday that its total vaccine sales fell 2.5% in the fourth quarter and 1.2% for the entire year, reaching 7.9 billion euros (roughly $9.5 billion) for all of 2025.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/sanofi-stands-firm-against-us-policy-tumult-it-predicts-vaccine-sales-dip-26)

---

### ğŸ‡ºğŸ‡¸ 'Relax your tight end': Novartis Super Bowl ad drafts NFL stars for cheeky prostate cancer testing push

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-28 16:56
- **é‡è¦æ€§**: â­â­

> A year after debuting its first Super Bowl ad, Novartis is returning to advertisingâ€™s biggest stage on another awareness-raising mission, this time focusing on boosting prostate cancer screening.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/marketing/novartis-super-bowl-ad-drafts-nfl-stars-cheeky-prostate-cancer-testing-push)

---

### ğŸ‡ºğŸ‡¸ Tenpoint scores FDA nod for vision-correction eye drop Yuvezzi, plans Q2 launch with $235M in tow

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-28 23:53
- **é‡è¦æ€§**: â­â­

> Combining two eye drops that have been on the market for at least 30 years each has earned Tenpoint Therapeutics an FDA approval for Yuvezzi, a treatment for presbyopia, a common, age-related condition that makes it difficult to focus on nearby objects. The company also said that it has raised $235 million to fund the launch of the product.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/tenpoint-scores-fda-nod-vision-correction-eye-drop-yuvezzi)

---

### ğŸ‡ºğŸ‡¸ AstraZeneca vows $15B China investment to boost cell therapy and radioconjugate capabilities

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-29 05:51
- **é‡è¦æ€§**: â­â­

> AstraZeneca has outlined plans to invest $15 billion in China through 2030, making a broad commitment to the country to enhance its capabilities in areas including cell therapies and radioconjugates.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/biotech/astrazeneca-vows-15b-china-investment-boost-cell-therapy-and-radioconjugate-capabilities)

---

### ğŸ‡ºğŸ‡¸ Antheia seals 2nd series C funding close, hitting more than $175M in a year

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-28 08:26
- **é‡è¦æ€§**: â­â­

> Biosynthesis specialist Antheia has topped off its series C funding with a second close, adding $24 million more to its haul. The financing lift brings Antheia's total funding over the past year to more than $175 million when combined with other capital and new contracts with the U.S. government, according to the company.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/manufacturing/antheia-seals-second-close-series-c-funding-hit-175m-year)

---

### ğŸ‡ºğŸ‡¸ STAT+: Lilly, Repertoire strike $2 billion autoimmune alliance

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-29 16:03
- **é‡è¦æ€§**: â­â­

> And other biotech news, brought to you by The Readout

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/2026/01/29/biotech-news-lilly-repertoire-strike-autoimmune-alliance/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: Pharmalittle: Weâ€™re reading about AstraZeneca investing in China, an abandoned overdose antidote, and more

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-29 14:23
- **é‡è¦æ€§**: â­â­

> AstraZeneca will invest $15 billion in China through 2030 to expand medicines manufacturing and research and development

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/pharmalot/2026/01/29/astrazeneca-hologen-kickbacks-overdose-lilly-china/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: Pharmalittle: Weâ€™re reading about Medicare drug prices, the EU-India trade deal, and more

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-28 14:00
- **é‡è¦æ€§**: â­â­

> The Trump administration released the next 15 drugs subject to Medicare price negotiation, including for the first time treatments administered in doctor offices

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/pharmalot/2026/01/28/medicare-pharma-india-europe-novo-lilly-advertising/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: Pharmalittle: Weâ€™re reading about pharma lobbying, an FDA gene-editing pathway, and more

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-26 14:05
- **é‡è¦æ€§**: â­â­

> The pharmaceutical industry, long one of the most powerful lobbies in Washington, is spending more than ever to influence the nationâ€™s capital

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/pharmalot/2026/01/26/pharma-lobbying-novo-genes-fda-patents/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ Fierce Pharma Asiaâ€”AZ's $15B China investment; Boehringer, Simcere's IBD deal; Daiichi's ADC growth push

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-29 15:08
- **é‡è¦æ€§**: â­

> AstraZeneca made a big commitment to China as CEO Pascal Soriot joined British Prime Minister Keir Starmer on a trip to the country. Boehringer Ingelheim secured a preclinical inflammatory bowel disease bispecific from Simcere. Daiichi Sankyo's U.S. chief talked about the successâ€”and challengesâ€”the company is seeing with Enhertu and Datroway. And more.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/az-15b-china-investment-boehringer-simcere-ibd-deal-daiichi-adc-growth-push)

---

### ğŸ‡ºğŸ‡¸ STAT+: Pharmalittle: Weâ€™re reading about a Roche obesity drug, a clash over 340B claims data, and more

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-27 14:17
- **é‡è¦æ€§**: â­

> Roche plans to launch Phase 3 studies of its leading obesity candidate this quarter after the drug led to significant weight loss in a mid-stage trial

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/pharmalot/2026/01/27/roche-obesity-menopause-china-lilly-340b-hospitals-bausch/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ Trump administration officials are at loggerheads over future of COVID vaccines: Axios

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-30 06:55

> Some officials in the Trump administration are at odds with others who are helping shape vaccine policy over whether to remove COVID vaccines from the U.S. market, according to a report from Axios.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/trump-administration-officials-are-loggerheads-over-covid-vaccines-report)

---

### ğŸ‡ºğŸ‡¸ Quince Therapeutics on the brink as steroid-in-blood-cell fails in rare genetic disease

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-30 09:57

> Quince Therapeuticsâ€™ novel method of delivering steroids in a patientâ€™s own red blood cells turned out to be a bust in ataxia-telangiectasia, a rare inherited disorder, with the company now planning to â€œpreserve cash and explore available options.â€

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/quince-therapeutics-teeters-edge-steroid-blood-cell-fails-rare-genetic-disease)

---

### ğŸ‡ºğŸ‡¸ Biopharma's rebound keeping pace so far

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-29 15:56

> This week on "The Top Line," we explore biopharma's rebound, dealmaking momentum and what's cutting through the noise in 2026.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/biopharmas-rebound-keeping-pace-so-far)

---

### ğŸ‡ºğŸ‡¸ Novo gets Chamber of Commerce backing in bid to bring IRA challenge to Supreme Court

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-29 14:36

> On Wednesday, the U.S. Chamber of Commerce filed an amicus brief calling on the Supreme Court to review a lower court decision that previously rejected Novo Nordisk's challenge of drug pricing provisions in the Inflation Reduction Act. As with other challenges to the IRA, the Chamber argued that the negotiations baked into the law are â€œillusory."

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/novo-gets-chamber-commerce-backing-bid-bring-ira-challenge-supreme-court)

---

### ğŸ‡ºğŸ‡¸ Hims &amp; Hers uses another Super Bowl ad to tackle healthcare affordability

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-29 13:21

> The minute-long ad, which debuted online Thursday ahead of its broadcast premiere during the Feb. 8 game, starts with a stark claim: â€œRich people live longer,â€ said by the adâ€™s narrator, the rapper and actor Common.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/marketing/hims-hers-uses-another-super-bowl-ad-tackle-healthcare-affordability)

---

### ğŸ‡ºğŸ‡¸ Takeda, still in a Vyvanse slog, lifts guidance as it looks to new wave of growth

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-29 11:26

> The gap between Vyvanse generic sales declines and growth from new products is narrowing, the Japanese company said on its third-quarter 2025 earnings call, which detailed financial performance from the nine months ending on Dec. 31.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/takeda-still-vyvanse-slog-lifts-guidance-it-looks-ahead-new-growth)

---

### ğŸ‡ºğŸ‡¸ As Roche eyes busy 2026, Vabysmo undershoots targets and Tecentriq fails early lung cancer study

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-29 10:41

> Roche is looking to a busy 2026 after 10 new molecules entered late-stage testing last year and as a potential launch of closely watched breast cancer candidate giredestrant draws near. But behind another strong earnings report, a miss from the star eye drug Vabysmo stood out.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/roche-eyes-busy-2026-vabysmo-undershoots-targets-tecentriq-fails-early-lung-cancer-study)

---

### ğŸ‡ºğŸ‡¸ Bayer broadcasts patient stories with Tony Romo calling plays in Nubeqa drive

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-29 10:12

> Bayer has unveiled the next play in its Nubeqa marketing strategy, tapping NFL quarterback-turned-CBS commentator Tony Romo for a campaign in support of its fast-growing prostate cancer drug.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/marketing/bayer-broadcasts-patient-stories-tony-romo-calling-plays-nubeqa-drive)

---

### ğŸ‡ºğŸ‡¸ The new rules of biopharma M&amp;A: 4 trends driving dealmaking this year

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-28 13:36

> As biopharma M&amp;A activity ramps back up, strategy is shifting to no longer focus on securing the next blockbuster drug, but instead to ink deals that build out capabilities across the entire drug development and commercialization process.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/biotech/new-rules-biopharma-ma-4-trends-driving-deal-making-year)

---

### ğŸ‡ºğŸ‡¸ Advocacy group files FOIA lawsuit to gain further clarity on Trump administration's MFN pricing deals

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-28 15:28

> Consumer advocacy organization Public Citizen has filed a Freedom of Information Act lawsuit against the Department of Health and Human Services and the Department of Commerce&nbsp;for failing to provide documents related to President Donald Trumpâ€™s most-favored nation drug pricing deals with Pfizer and Eli Lilly.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/public-citizen-files-foia-lawsuits-against-trump-administration-mfn-pricing-deals-pfizer)

---

### ğŸ‡ºğŸ‡¸ Halozyme catches M&amp;A wave to snap up Surf Bio in delivery tech deal worth up to $400M

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-28 12:05

> Shortly after acquiring Elektrofi to beef up its subcutaneous drug delivery offerings, Halozyme Therapeutics has struck another deal to purchase Surf Bio.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/halozyme-catches-ma-wave-snap-surf-bio-delivery-tech-deal-worth-400m)

---

### ğŸ‡ºğŸ‡¸ American Academy of Pediatrics' updated immunization schedule rebukes CDC's drastic cutbacks

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-28 13:15

> The pediatric medical group recommends children be vaccinated against 18 diseases, as opposed to the federal government's recent reduction to 11.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/providers/american-academy-pediatrics-updated-immunization-schedule-rebukes-cdcs-drastic-changes)

---

### ğŸ‡ºğŸ‡¸ Teva, after 3rd straight year of growth, expects downturn in 2026

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-28 11:01

> With a third consecutive year of sales growth under its belt, the company is expecting flat or slightly down revenues in 2026, it said.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/teva-third-year-growth-innovative-products-expects-downturn-2026)

---

### ğŸ‡ºğŸ‡¸ STAT+: Up and down the ladder: The latest comings and goings

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-30 17:06

> From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/pharmalot/2026/01/30/pharma-biotech-jobs-abbvie-merck-biontech-moderna-takeda-novo/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: New rule would force PBMs to disclose drug rebates and other fees

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-30 15:48

> The proposal would mark a significant change for the secretive PBM industry, which often shields crucial data from its clients.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/2026/01/30/pbm-drug-rebate-transparency-proposed-rule-department-of-labor/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: AstraZeneca looks to China for obesity drug candidates

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-30 14:36

> And other biotech news brought to you by The Readout

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/2026/01/30/biotech-news-astrazeneca-china-obesity-drug-candidates/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: Pharmalittle: Weâ€™re reading about TrumpRx questions, drugmakers lowering some prices, and more

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-30 14:35

> Three U.S. senators sent a letter to the HHS Office of Inspector General raising questions about TrumpRx â€” whose structure has yet to be detailed

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/pharmalot/2026/01/30/trump-telehealth-obesity-pbm-insulin-astrazeneca-china/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: States are the next vaccine battleground

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-29 17:07

> This is the web edition of STAT's D.C. Diagnosis newsletter.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/2026/01/29/state-vaccine-mandates-health-care-ice-minnesota-dc-diagnosis-newsletter/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: Oz, other officials meet with key senators to push Trumpâ€™s ideas for lower drug prices

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-29 16:30

> Trump wants lawmakers to force pharma companies to lower their prices, but it's not clear the GOP is on board.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/2026/01/29/mehmet-oz-senate-finance-committee-meeting-most-favored-nations-drug-pricing/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: How Opvee, Indiviorâ€™s powerful overdose antidote, went bust

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-29 09:30

> Opvee reverses opioid overdose more quickly than Narcan. It also can cause withdrawal symptoms. Harm reduction advocates fought it, and won.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/2026/01/29/why-opvee-overdose-antidote-failed-harm-reduction-community-opposition/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: Eli Lilly expands work on gene therapies for hearing

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-28 14:49

> And other biotech news brought to you by The Readout

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/2026/01/28/biotech-news-eli-lillly-expands-gene-therapy-for-hearing/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: More high-income countries have used compulsory licenses to gain access to meds, study finds

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-28 13:00

> More high-income countries have used compulsory licenses to gain access to meds, study finds.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/pharmalot/2026/01/28/pharma-compulsory-licenses-patents-medicines-wto/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: Startup Altido Therapeutics pursues CAR-T for glioblastoma tumors

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-28 09:30

> Glioblastoma is almost always fatal. Altido Bio is trying to commercialize a CAR-T cell therapy that has shown rare promise.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/2026/01/28/gene-therapy-nick-leschly-startup-altido-therapeutics-targets-glioblastoma/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: New startup to develop a GLP-1 drug for addiction

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-27 14:40

> And other biotech news brought to you by The Readout newsletter

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/2026/01/27/biotech-news-glp-1-drug-for-addiction-startup/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: Roche moves obesity drug to pivotal trials after mid-stage success

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-27 08:08

> Roche plans to launch pivotal studies of an experimental weight loss drug after a successful mid-stage trial.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/2026/01/27/roche-ct388-trials-weight-loss-obesity/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: Hospital group wants Trump administration to block a new Lilly policy on 340B claims data

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-26 21:11

> The American Hospital Association is asking the Trump administration to stop Eli Lilly from enacting a new policy as part of the 340B drug discount program.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/pharmalot/2026/01/26/pharma-lilly-medicines-hospitals-340b/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: Launch of Wegovy pill looks to be going strong so far

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-26 14:30

> And more biotech news brought to you by The Readout

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/2026/01/26/biotech-news-wegovy-pill-launch-holds-promise-novo-nordisk/?utm_campaign=rss)

---

## ç›‘ç®¡å®¡æ‰¹ | Regulatory

### ğŸ‡ºğŸ‡¸ List of Determinations Including Written Request

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-30 21:25
- **é‡è¦æ€§**: â­â­â­â­

> In accordance with section 505A(e)(1) of the Act, as amended by FDAAA (Pub. L. No. 110-85), the following list identifies those approved drugs for which a pediatric exclusivity determination was made, on or after September 27, 2007.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/development-resources/list-determinations-including-written-request)

---

### ğŸ‡ºğŸ‡¸ Competitive Generic Therapy Approvals

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-30 18:44
- **é‡è¦æ€§**: â­â­â­â­

> Explore the FDAâ€™s Competitive Generic Therapy Approvals page, offering insights into the program designed to encourage generic drug competition. Access information about approved CGT products and find resources, including a downloadable CGT approvals spreadsheet.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/generic-drugs/competitive-generic-therapy-approvals)

---

### ğŸ‡ºğŸ‡¸ Clinical Decision Support Software

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-29 16:11
- **é‡è¦æ€§**: â­â­â­

> This guidance clarifies the scope of FDAâ€™s oversight of clinical decision support software intended for health care professionals (HCPs) as devices.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-decision-support-software)

---

### ğŸ‡ºğŸ‡¸ Non-Compliance Letters under 505B(d)(1) of the Federal Food, Drug, and Cosmetic Act

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-30 20:54
- **é‡è¦æ€§**: â­â­

> Section 505B(d)(1) requires FDA to send a PREA Non-Compliance letter to sponsors who have failed to submit their pediatric assessments required under PREA by the final due date, have failed to seek or obtain a deferral or deferral extension.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/development-resources/non-compliance-letters-under-505bd1-federal-food-drug-and-cosmetic-act)

---

### ğŸ‡ºğŸ‡¸ Untitled Letters

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-30 20:37
- **é‡è¦æ€§**: â­â­

> These letters are supplied by the CDER Freedom of Information Office and only cover Office of Prescription Drug Promotion's untitled letters. FDA may have redacted or edited some of the letters to remove confidential information.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/warning-letters-and-notice-violation-letters-pharmaceutical-companies/untitled-letters)

---

### ğŸ‡ºğŸ‡¸ Registered Outsourcing Facilities

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-30 18:58
- **é‡è¦æ€§**: â­â­

> Discover FDA's comprehensive list of registered outsourcing facilities engaged in human drug compounding. Get the latest updates, compliance guidelines, and resources to ensure safe, high-quality compounded medications. Explore regulations and stay informed with verified facility details.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities)

---

### ğŸ‡ºğŸ‡¸ Drugs@FDA Data Files

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-30 16:12
- **é‡è¦æ€§**: â­â­

> Drugs@FDA Downloadable Data File in ZIP format, Data Definitions, and Entity Relationship Diagram (ERD)

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/drug-approvals-and-databases/drugsfda-data-files)

---

### ğŸ‡ºğŸ‡¸ IND Application Procedures: Interactions with FDA

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-30 14:49
- **é‡è¦æ€§**: â­â­

> Sponsors of IND applications may obtain advice and guidance from FDA at any stage of IND development. Learn more.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/investigational-new-drug-ind-application/ind-application-procedures-interactions-fda)

---

### ğŸ‡ºğŸ‡¸ GDUFA IV: Fiscal Years 2028 â€“ 2032

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-29 22:36
- **é‡è¦æ€§**: â­â­

> Information related to FDAâ€™s preparation for the fourth reauthorization of GDUFA will be hosted on this page as it becomes available.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/industry/generic-drug-user-fee-amendments/gdufa-iv-fiscal-years-2028-2032)

---

### ğŸ‡ºğŸ‡¸ IND Application Procedures: Exemptions from IND Requirements

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-30 15:17
- **é‡è¦æ€§**: â­

> Before submitting an IND application, investigators should refer to the Guidance&nbsp;for Clinical Investigators, Sponsors, and IRBs: Investigational New Drug Applications (INDs)â€” Determining Whether Human Research Studies Can Be Conducted Without an IND&nbsp;to determine whether they are exempt.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/investigational-new-drug-ind-application/ind-application-procedures-exemptions-ind-requirements)

---

### ğŸ‡ºğŸ‡¸ IND Applications for Clinical Investigations: Overview

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-30 14:47
- **é‡è¦æ€§**: â­

> An overview of terms related to IND Applictions

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/investigational-new-drug-ind-application/ind-applications-clinical-investigations-overview)

---

### ğŸ‡ºğŸ‡¸ IND Application Reporting: Protocol Amendments

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-30 14:47
- **é‡è¦æ€§**: â­

> Once an IND application is in effect, the sponsor of the application may amend the application as needed to ensure that the clinical investigations are conducted according to protocols included in the IND application.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/investigational-new-drug-ind-application/ind-application-reporting-protocol-amendments)

---

### ğŸ‡ºğŸ‡¸ IND Application Procedures: Investigator's Responsibilities

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-30 15:15

> This page provides the key points that investigators should consider in order to understand their responsibilities regarding an IND application.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/investigational-new-drug-ind-application/ind-application-procedures-investigators-responsibilities)

---

### ğŸ‡ºğŸ‡¸ IND Application Reporting: Overview

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-30 15:15

> IND Application Reporting: Overview

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/investigational-new-drug-ind-application/ind-application-reporting-overview)

---

### ğŸ‡ºğŸ‡¸ Generic Drug User Fee Amendments

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-30 15:03

> This page features news and information for industry and stakeholders about GDUFA, its fee structure, payment methods, and related information.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/industry/fda-user-fee-programs/generic-drug-user-fee-amendments)

---

### ğŸ‡ºğŸ‡¸ Generic Drug Facilities, Sites and Organization Lists

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-30 14:59

> Generic Drug Facilities, Sites and Organization Lists

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/industry/generic-drug-user-fee-amendments/generic-drug-facilities-sites-and-organization-lists)

---

### ğŸ‡ºğŸ‡¸ General Drug Categories

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-30 14:46

> General Drug Categories

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/investigational-new-drug-ind-application/general-drug-categories)

---

### ğŸ‡ºğŸ‡¸ Addresses to Send Applications

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-30 14:46

> Addresses to Send Applications

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/investigational-new-drug-ind-application/addresses-send-applications)

---

### ğŸ‡ºğŸ‡¸ Human Drug Compounding Outsourcing Facility Fees

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-30 12:43

> Human Drug Compounding Outsourcing Facility Fees

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/industry/fda-user-fee-programs/human-drug-compounding-outsourcing-facility-fees)

---

### ğŸ‡ºğŸ‡¸ OMUFA Reauthorization: Fiscal Years 2026 - 2030

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-29 17:20

> This page is the main website for information pertaining to OMUFA reauthorization activities, including high level meeting minutes with industry while negotiations are ongoing.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/industry/fda-user-fee-programs/omufa-reauthorization-fiscal-years-2026-2030)

---

## å•†ä¸šåŠ¨æ€ | Business/M&A

### ğŸ‡ºğŸ‡¸ Argo Biopharma doses first patient in phase 2b trial of BWâ€‘20829

- **æ¥æº**: Pharma Times
- **æ—¶é—´**: 2026-01-28 14:20
- **é‡è¦æ€§**: â­â­â­

> siRNA therapeutic progresses in global study for patients with elevated Lp(a)

ğŸ”— [é˜…è¯»åŸæ–‡](https://pharmatimes.com/news/argo-biopharma-doses-first-patient-in-phase-2b-trial-of-bw-20829/)

---

### ğŸ‡ºğŸ‡¸ Otsuka Pharmaceuticalâ€™s Dawnzera receives EC approval for hereditary angioedema prevention

- **æ¥æº**: Pharma Times
- **æ—¶é—´**: 2026-01-26 12:05
- **é‡è¦æ€§**: â­â­

> Dawnzera showed an 81% reduction in the four-weekly rate of HAE attacks compared to placebo

ğŸ”— [é˜…è¯»åŸæ–‡](https://pharmatimes.com/news/otsuka-pharmaceuticals-dawnzera-receives-ec-approval-for-hereditary-angioedema-prevention/)

---

### ğŸ‡ºğŸ‡¸ CERo reports encouraging early data from phase 1 trial of CERâ€‘1236

- **æ¥æº**: Pharma Times
- **æ—¶é—´**: 2026-01-29 10:59
- **é‡è¦æ€§**: â­

> CERâ€‘T therapy shows initial safety signals and prompts protocol expansion

ğŸ”— [é˜…è¯»åŸæ–‡](https://pharmatimes.com/news/cero-reports-encouraging-early-data-from-phase-1-trial-of-cer-1236/)

---

### ğŸ‡ºğŸ‡¸ ENA Respiratory begins dosing in phase 2 study of INNAâ€‘051 nasal spray

- **æ¥æº**: Pharma Times
- **æ—¶é—´**: 2026-01-29 10:44
- **é‡è¦æ€§**: â­

> Trial to assess whether onceâ€‘weekly treatment can reduce symptomatic viral respiratory infections

ğŸ”— [é˜…è¯»åŸæ–‡](https://pharmatimes.com/news/ena-respiratory-begins-dosing-in-phase-2-study-of-inna-051-nasal-spray/)

---

### ğŸ‡ºğŸ‡¸ BioMed X launches kidney disease project in partnership with the government of Barbados

- **æ¥æº**: Pharma Times
- **æ—¶é—´**: 2026-01-27 13:54
- **é‡è¦æ€§**: â­

> Initiative focuses on population-specific molecular profiling

ğŸ”— [é˜…è¯»åŸæ–‡](https://pharmatimes.com/news/biomed-x-launches-kidney-disease-project-in-partnership-with-the-government-of-barbados/)

---

### ğŸ‡ºğŸ‡¸ Akari files new patent and advances second ADC targeting CEACAM5

- **æ¥æº**: Pharma Times
- **æ—¶é—´**: 2026-01-28 14:15

> Company strengthens pipeline with AKTX-102 as it broadens its intellectual property estate

ğŸ”— [é˜…è¯»åŸæ–‡](https://pharmatimes.com/news/akari-files-new-patent-and-advances-second-adc-targeting-ceacam5/)

---

### ğŸ‡ºğŸ‡¸ Gedeon Richter UK takes over UK rights to cariprazine

- **æ¥æº**: Pharma Times
- **æ—¶é—´**: 2026-01-27 13:47

> Company strengthens its neuropsychiatry portfolio after marketing transfer from Recordati

ğŸ”— [é˜…è¯»åŸæ–‡](https://pharmatimes.com/news/gedeon-richter-uk-takes-over-uk-rights-to-cariprazine/)

---

### ğŸ‡ºğŸ‡¸ Corcept Therapeuticsâ€™ relacorilant plus nab-paclitaxel shows positive results in ovarian cancer

- **æ¥æº**: Pharma Times
- **æ—¶é—´**: 2026-01-26 11:57

> Ovarian cancer is the fifth leading cause of deaths from cancer in women

ğŸ”— [é˜…è¯»åŸæ–‡](https://pharmatimes.com/news/corcept-therapeutics-relacorilant-plus-nab-paclitaxel-shows-positive-results-in-ovarian-cancer/)

---


---

*Generated by Pharma Daily - åˆ¶è¯èµ„è®¯èšåˆç³»ç»Ÿ*

*2026-02-02 04:23:49*